READ THE FULL ARTICLEis the only listed company on the ASX which is tackling this side effect problem head-on.
Recent animal study has shown that Noxopharm’s SOF-VAC mRNA vaccine enhancer significantly reduces mRNA-driven inflammation by as high as 50%.
“This enhancer works on specific cell receptors in the body to block inflammation at its source,” CEO of Noxopharm, Dr Gisela Mautner, told *.
mRNA is the next big thing in medicine. Here’s why Noxopharm could be the ASX front runner in this field
READ THE FULL ARTICLE is the only listed company on the ASX...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
0.010(14.7%) |
Mkt cap ! $22.79M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 8.0¢ | 6.9¢ | $33.53K | 452.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.8¢ | 7499 | 1 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.9¢ |
Change
0.010 ( 17.9 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.9¢ | 7.5¢ | 40639 | ||
| Last updated 13.38pm 15/05/2024 ? | |||||
| NOX (ASX) Chart |